Tags

Type your tag names separated by a space and hit enter

Simultaneous confirmation and differentiation of human T-lymphotropic virus types I and II infection by modified western blot containing recombinant envelope glycoproteins.
Transfusion. 1993 Nov-Dec; 33(11):925-9.T

Abstract

A modified Western blot (WB) that includes both shared (r21e) and unique recombinant envelope proteins from human T-lymphotropic virus (HTLV) type I (rgp46I) and type II (rgp46II) was compared to conventional HTLV serologic tests in 379 United States blood donors and individuals residing in diverse geographic regions, and the specimens were categorized as positive (n = 158), indeterminate (n = 158), or negative (n = 63) for HTLV infection. Of the 158 HTLV-I/II-positive specimens (66 requiring radioimmunoprecipitation assay [RIPA] for confirmation), 156 reacted concordantly with r21e, gag, and either rgp46I or rgp46II, thus eliminating the need for RIPA in all but two specimens and yielding a test sensitivity of 98.7 percent. Of the 158 indeterminate and 63 negative specimens, none reacted with r21e and rgp46I or rgp46II, yielding a test specificity of 100 percent. Furthermore, analysis of an additional 184 consecutive specimens from a retrovirology reference laboratory demonstrated that the modified WB correctly identified 27 of 28 HTLV-I specimens and all 13 HTLV-II specimens, with a test sensitivity of 97.6 percent. None of specimens that were indeterminate or nonreactive in conventional WB and/or RIPA and none of the screening enzyme immunoassay-negative specimens reacted with r21e and either rgp46I or rgp46II, for a test specificity of 100 percent. Thus, the modified WB appears to be highly sensitive and specific for simultaneous detection and discrimination of HTLV-I from HTLV-II and has the advantage of being a one-step assay that is easily performed in all types of laboratory settings and allows rapid, reliable, and standardized testing for HTLV-I/II infection.

Authors+Show Affiliations

Department of Health Sciences and Epidemiology, Naval Health Research Center, San Diego, California.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

7903127

Citation

Brodine, S K., et al. "Simultaneous Confirmation and Differentiation of Human T-lymphotropic Virus Types I and II Infection By Modified Western Blot Containing Recombinant Envelope Glycoproteins." Transfusion, vol. 33, no. 11, 1993, pp. 925-9.
Brodine SK, Kaime EM, Roberts C, et al. Simultaneous confirmation and differentiation of human T-lymphotropic virus types I and II infection by modified western blot containing recombinant envelope glycoproteins. Transfusion. 1993;33(11):925-9.
Brodine, S. K., Kaime, E. M., Roberts, C., Turnicky, R. P., & Lal, R. B. (1993). Simultaneous confirmation and differentiation of human T-lymphotropic virus types I and II infection by modified western blot containing recombinant envelope glycoproteins. Transfusion, 33(11), 925-9.
Brodine SK, et al. Simultaneous Confirmation and Differentiation of Human T-lymphotropic Virus Types I and II Infection By Modified Western Blot Containing Recombinant Envelope Glycoproteins. Transfusion. 1993 Nov-Dec;33(11):925-9. PubMed PMID: 7903127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Simultaneous confirmation and differentiation of human T-lymphotropic virus types I and II infection by modified western blot containing recombinant envelope glycoproteins. AU - Brodine,S K, AU - Kaime,E M, AU - Roberts,C, AU - Turnicky,R P, AU - Lal,R B, PY - 1993/11/1/pubmed PY - 1993/11/1/medline PY - 1993/11/1/entrez SP - 925 EP - 9 JF - Transfusion JO - Transfusion VL - 33 IS - 11 N2 - A modified Western blot (WB) that includes both shared (r21e) and unique recombinant envelope proteins from human T-lymphotropic virus (HTLV) type I (rgp46I) and type II (rgp46II) was compared to conventional HTLV serologic tests in 379 United States blood donors and individuals residing in diverse geographic regions, and the specimens were categorized as positive (n = 158), indeterminate (n = 158), or negative (n = 63) for HTLV infection. Of the 158 HTLV-I/II-positive specimens (66 requiring radioimmunoprecipitation assay [RIPA] for confirmation), 156 reacted concordantly with r21e, gag, and either rgp46I or rgp46II, thus eliminating the need for RIPA in all but two specimens and yielding a test sensitivity of 98.7 percent. Of the 158 indeterminate and 63 negative specimens, none reacted with r21e and rgp46I or rgp46II, yielding a test specificity of 100 percent. Furthermore, analysis of an additional 184 consecutive specimens from a retrovirology reference laboratory demonstrated that the modified WB correctly identified 27 of 28 HTLV-I specimens and all 13 HTLV-II specimens, with a test sensitivity of 97.6 percent. None of specimens that were indeterminate or nonreactive in conventional WB and/or RIPA and none of the screening enzyme immunoassay-negative specimens reacted with r21e and either rgp46I or rgp46II, for a test specificity of 100 percent. Thus, the modified WB appears to be highly sensitive and specific for simultaneous detection and discrimination of HTLV-I from HTLV-II and has the advantage of being a one-step assay that is easily performed in all types of laboratory settings and allows rapid, reliable, and standardized testing for HTLV-I/II infection. SN - 0041-1132 UR - https://www.unboundmedicine.com/medline/citation/7903127/Simultaneous_confirmation_and_differentiation_of_human_T_lymphotropic_virus_types_I_and_II_infection_by_modified_western_blot_containing_recombinant_envelope_glycoproteins_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0041-1132&date=1993&volume=33&issue=11&spage=925 DB - PRIME DP - Unbound Medicine ER -